CST626

Overview

CST626 is a PROTAC degrader targeting IAP , with DC 50 values of 0.7 nM, 2.4 nM and 6.2 nM against XIAP , cIAP1 and cIAP2 , respectively. This compound recruits the VHL E3 ubiquitin ligase to form a heterotrimeric complex, thereby inducing ubiquitination and proteasomal degradation of the target proteins. CST626 also exhibits certain degrading activity against VHL30 and VHL19 . CST626 inhibits the proliferation and induces apoptosis of various hematologic tumor cell lines, and its anti-tumor effect is further enhanced when used in combination with TNF-α. CST626 can be used in research related to multiple myeloma, acute myeloid leukemia and diffuse large B-cell lymphoma. (Pink: IAP and XIAP ligand ( HY-175925 ); Blue: VHL ligand ( HY-112078 ); Black: linker).

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Acute Myeloid Leukemia | Products > Disease Areas > Diffuse Large B-cell Lymphoma | Products > Disease Areas > Multiple Myeloma | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > IAP | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-149924
• CAS No.: 3033993-13-1
• Molecular Formula: C61H82N8O9S
• Molecular Weight: 1103.42
• Purity: 99.60%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (2.27 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source